BioCentury | Dec 27, 2019
Clinical News

Spring Bank’s HBV therapy on hold after signs of liver damage

...solid tumor and lymphoma, for “business reasons.” Merck gained MK-4621 via its 2017 acquisition of Rigontec GmbH...
BioCentury | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

...of the strongest immune responses by a virus in a tumor.” Vollmer was CSO at Rigontec GmbH...
BioCentury | Oct 1, 2019
Finance

STING start-up STipe first to emerge from Novo incubator

...former CEO of Rigontec GmbH, will be STipe’s executive chairman. Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
BioCentury | Jul 31, 2019
Finance

How Wellington closed its largest fund yet at €210M

...Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria...
...two therapeutics companies, two medtechs and a diagnostics company. One, the acquisition of immuno-oncology company Rigontec GmbH...
...milestones. The upfront payment was nearly a 4x return on the €29.3 million ($32.7 million) Rigontec...
BioCentury | Jul 13, 2018
Financial News

Forbion raises €270M, surpassing target for fourth fund

...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH...
...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
BioCentury | Jul 13, 2018
Finance

Forbion builds immunity

...its third life sciences fund included acquisitions of NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH...
...front plus up to $975 million in milestones, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
BioCentury | Jul 11, 2018
Financial News

Forbion raises €270M, surpassing target for fourth fund

...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH...
...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
BioCentury | Apr 3, 2018
Targets & Mechanisms

Sensor sensibility

...a company that targeted the RIG-I pathway, that developed RIG-I agonists for immuno-oncology. The company [Rigontec GmbH]...
BioCentury | Jan 5, 2018
Financial News

Boehringer increases investment fund, expands focus

...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH...
...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec...
...Ingelheim GmbH, Ingelheim, Germany Mary Romeo Boehringer Ingelheim GmbH Flanders Institute for Biotechnology (VIB) GlaxoSmithKline plc Merck & Co. Inc. Okairos AG Rigontec GmbH Aelin...
BioCentury | Jan 3, 2018
Financial News

Boehringer Ingelheim enlarges investment fund

...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH...
...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec...
...BioCentury Extra, Dec. 11, 2017) . Mary Romeo Boehringer Ingelheim GmbH Flanders Institute for Biotechnology (VIB) Merck & Co. Inc. Rigontec GmbH Aelin...
Items per page:
1 - 10 of 29
BioCentury | Dec 27, 2019
Clinical News

Spring Bank’s HBV therapy on hold after signs of liver damage

...solid tumor and lymphoma, for “business reasons.” Merck gained MK-4621 via its 2017 acquisition of Rigontec GmbH...
BioCentury | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

...of the strongest immune responses by a virus in a tumor.” Vollmer was CSO at Rigontec GmbH...
BioCentury | Oct 1, 2019
Finance

STING start-up STipe first to emerge from Novo incubator

...former CEO of Rigontec GmbH, will be STipe’s executive chairman. Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
BioCentury | Jul 31, 2019
Finance

How Wellington closed its largest fund yet at €210M

...Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria...
...two therapeutics companies, two medtechs and a diagnostics company. One, the acquisition of immuno-oncology company Rigontec GmbH...
...milestones. The upfront payment was nearly a 4x return on the €29.3 million ($32.7 million) Rigontec...
BioCentury | Jul 13, 2018
Financial News

Forbion raises €270M, surpassing target for fourth fund

...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH...
...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
BioCentury | Jul 13, 2018
Finance

Forbion builds immunity

...its third life sciences fund included acquisitions of NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH...
...front plus up to $975 million in milestones, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
BioCentury | Jul 11, 2018
Financial News

Forbion raises €270M, surpassing target for fourth fund

...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH...
...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
BioCentury | Apr 3, 2018
Targets & Mechanisms

Sensor sensibility

...a company that targeted the RIG-I pathway, that developed RIG-I agonists for immuno-oncology. The company [Rigontec GmbH]...
BioCentury | Jan 5, 2018
Financial News

Boehringer increases investment fund, expands focus

...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH...
...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec...
...Ingelheim GmbH, Ingelheim, Germany Mary Romeo Boehringer Ingelheim GmbH Flanders Institute for Biotechnology (VIB) GlaxoSmithKline plc Merck & Co. Inc. Okairos AG Rigontec GmbH Aelin...
BioCentury | Jan 3, 2018
Financial News

Boehringer Ingelheim enlarges investment fund

...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH...
...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec...
...BioCentury Extra, Dec. 11, 2017) . Mary Romeo Boehringer Ingelheim GmbH Flanders Institute for Biotechnology (VIB) Merck & Co. Inc. Rigontec GmbH Aelin...
Items per page:
1 - 10 of 29